Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Lexicon Pharmaceuticals (NASDAQ:LXRX) and raises the price target from $6 to $8.

May 31, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup maintains a Buy rating on Lexicon Pharmaceuticals and raises the price target from $6 to $8.
Citigroup's decision to maintain a Buy rating on Lexicon Pharmaceuticals and raise the price target from $6 to $8 indicates a positive outlook for the company's stock. This news is likely to have a positive impact on LXRX's stock price in the short term as it reflects increased confidence in the company's prospects by a major financial institution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100